Clinical Trials | November 26, 2025
Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
This approval authorizes the company to export Ibuprofen to the Chinese markets
The consignment of USFDA qualified Metformin (1000mg) was received by the province of Mendoza for distribution in the public health system
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
Subscribe To Our Newsletter & Stay Updated
